Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)

Vanda Pharmaceuticals

Status and phase: Enrolling; Phase 3

Conditions: Sleep Disorders, Circadian Rhythm; Chronobiology Disorders; Sleep Wake Disorders

Treatments: Drug: Tasimelteon; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT04652882

VP-VEC-162-3502

Details and patient eligibility

About

This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female participants with DSWPD.

Enrollment: 70 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Ability and acceptance to provide written informed consent.
• A confirmed clinical diagnosis of Delayed Sleep-Wake Phase Disorder (DSWPD).
• Men or women between 18 - 75 years, inclusive.
• Body Mass Index (BMI) of ≥ 18 and ≤ 35 kg/m^2.

Exclusion criteria

• Exacerbation of an existing psychiatric condition that requires change in treatment or intervention in the past 3 months.
• Major surgery, trauma, illness, general anesthesia, or immobility for 3 or more days within the last 30 days.
• Pregnancy, recent pregnancy (within 6 weeks), or women who are breastfeeding.
• A positive test for substances of abuse.
• Current tobacco user.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

70 participants in 2 patient groups, including a placebo group

Tasimelteon

Experimental group

Treatment:

Drug: Tasimelteon

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo